FDA Reopens Comment Period for Levothyroxine Sodium Therapeutic Equivalence Meeting

Summary

The FDA is extending the comment period for a public meeting on the therapeutic equivalence of levothyroxine sodium until September 23, 2005, in response to a request for an extension, following a public meeting held on May 23, 2005, involving FDA staff and representatives from medical societies.